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Abstract
In this viewpoint, we summarize the relevance of thromboinflammation in COVID-19 and discuss potential
mechanisms of endothelial injury as a key point for the development of lung and distant organ dysfunction, with a
focus on direct viral infection and cytokine-mediated injury. Entanglement between inflammation and coagulation
and resistance to heparin provide a rationale to consider other therapeutic approaches in order to preserve
endothelial function and limit microthrombosis, especially in severe forms. These strategies include nebulized
heparin, N-acetylcysteine, plasma exchange and/or fresh frozen plasma, plasma derivatives to increase the level of
endogenous anticoagulants (tissue factor pathway inhibitor, activated protein C, thrombomodulin, antithrombin),
dipyridamole, complement blockers, different types of stem cells, and extracellular vesicles. An integrated therapy
including these drugs has the potential to improve outcomes in COVID-19.
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Background
SARS-CoV-2 predominantly affects the lung, with pos-
sible development of acute respiratory distress syndrome
(ARDS) requiring admission to intensive care units.
However, several cases of multiple organ dysfunction
have been reported and the pathogenic mechanisms of
other organ involvement are far from being elucidated.
Even though organ dysfunction may be related to low
tissue oxygenation, other causes should be considered:
first, a maladaptive immune response characterized by a
plethora of inflammatory mediators; second, a direct
viral infection of different tissues: indeed, SARS-CoV-2
enters target cells through the interaction between its
spike proteins and ACE2 receptor, which is located on
many types of epithelial (lung, kidney, gut) and endothe-
lial cells. Varga and coworkers actually demonstrated the
presence of SARS-CoV-2 within endothelial cells of dif-
ferent organs [1].
These findings suggest that endothelial cell injury may
play a key role in the pathogenic mechanisms of both
lung and distant organ injury. Quiescent endothelial cells
maintain microvascular integrity exerting anti-
inflammatory, anti-thrombotic, and vasodilatory activ-
ities. However, under pathologic conditions, endothelial
cell homeostasis can be altered causing dysfunction of
coagulation, complement, fibrinolysis, and kinins cas-
cades. Even though primary efforts should be focused on
drugs directly acting on SARS-CoV-2 replication, sec-
ondary mechanisms of tissue injury also represent at-
tractive targets: among these, activation of the
coagulation pathway due to endothelial injury plays a
pivotal role [2].
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Main text
In a series of 26 autopsies in COVID-19 patients, the
presence of a diffuse erythrocyte aggregation in renal
peritubular and glomerular capillaries, with signs of
endothelial activation and segmental fibrin thrombi, was
observed [3]. Similar results were also found in the lungs
and other organs [4]. These findings suggest that throm-
boinflammation is a key feature of SARS-CoV-2 infec-
tion, especially in the lungs [5, 6]. Furthermore, higher
fibrin degradation product (FDP) levels, longer pro-
thrombin time, and activated partial thromboplastin
time are associated with a poor prognosis: of note, 71.4%
of non-survivors met the criteria of disseminated intra-
vascular coagulation (DIC) during their hospital stay in
comparison to 0.6% of survivors [7]. Consistently, other
studies showed higher D-dimer levels,
thrombocytopenia, diffuse acute pulmonary embolism
with normal lower-limb compression ultrasonography,
acro-ischemia, skin bulla, and dry gangrene [8, 9].
For these reasons, heparin has been extensively used
in COVID-19 patients [10]. Unfortunately, coagulation
pathway activation remained significantly stronger in
non-survivors despite heparin use, suggesting that, in
this setting of explosive activation of coagulation, stand-
ard thromboprophylactic doses of subcutaneous heparin
may be inadequate and therapeutic doses indicated in
severe cases. Another aspect is that, apart from anti-
coagulant properties, anti-inflammatory effects of hep-
arin may antagonize endothelial dysfunction [11].
Several immunomodulatory properties have been associ-
ated with unfractionated heparin (UH), which can inacti-
vate inflammatory cytokines, inhibit neutrophil
chemotaxis and leukocyte migration, neutralize comple-
ment factor C5a and sequester acute phase proteins
[12]; however, these biological effects have not yet been
fully elucidated for LMWH. Furthermore, the risk of
hemorrhagic complications is increased, and special cau-
tion is needed not only in patients with impairment of
renal function, one of the most frequent complications
of COVID-19 patients, but also in those with normal
renal function whenever higher therapeutic doses of
heparin are needed. In these settings, monitoring of Fac-
tor Xa is recommended in order to limit hemorrhagic
risk.
Entanglement between inflammation and coagulation
and resistance to heparin opened new prospects for
therapies: the war to the knife against thromboinflamma-
tion to protect microvascular endothelial cells in
COVID-19 must rely on alternative strategies that we
propose in the following 7 points:
1. Nebulized heparin has been shown to ameliorate
pulmonary coagulopathy and reduce the need for
mechanical ventilation in ARDS: other studies did
not confirm these data, probably because of ARDS
heterogeneity. However, since COVID-19-
associated lung injury is characterized by diffuse
microthrombosis and endothelial dysfunction, neb-
ulized heparin could represent a potential thera-
peutic approach, limiting bleeding risk and
increasing its effectiveness [13].
2. Taking into account the presence of systemic
inflammation, N-acetylcysteine (e.v./oral,
nebulization, or inhalation) may protect from
oxidative stress-mediated endothelial damage,
which activates the highly thrombotic subtype of
DIC observed in COVID-19. In fact, N-acetylcys-
teine binds to glutamine and glycine generating the
powerful antioxidant known as glutathione that has
been shown to counteract the inflammatory re-
sponse in pneumonia [14, 15].
3. In selected cases of coagulation activation and
multiple organ failures, plasma exchange (PEX)
could be considered. However, since PEX is not an
available option for all critically ill patients in an
emergency setting, high doses of fresh frozen
plasma (FFP) can represent an alternative, providing
factors capable of preventing fibrin formation at
different levels of the coagulation cascade, with a
similar mechanism to that observed in thrombotic
microangiopathy [16, 17]. In these cases, indication
for plasma infusion is not related to immunological
reasons (administration of immunoglobulins against
SARS-CoV-2) but aimed at providing natural anti-
coagulants and cofactors which are pathologically
consumed.
4. Another interesting therapeutic option is the use of
plasma derivatives capable of increasing the level of
endogenous anticoagulants, such as tissue factor
pathway inhibitor (TFPI), activated protein C
(APC), thrombomodulin (TM), and antithrombin
(AT). Since alveolar epithelium is the main source
of tissue factor (TF), a major initiator of the
extrinsic coagulation cascade in acute lung injury
(ALI), TFPI could limit coagulation activation and
cell damage. Preclinical models of ARDS showed
positive results with nebulized recombinant human
TFPI [18]. Similar data were obtained with
nebulized APC administration in animal models of
ALI, whereas e.v. administration showed negative
results in patients with severe sepsis (PROWESS-
Shock). ART-123 is a recombinant human soluble
TM with anticoagulant and anti-inflammatory
properties shown to improve outcome in patients
with ARDS and DIC [19]. Furthermore, nebulized
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AT improved pulmonary coagulopathy and fibrin-
olysis in an animal septic model of ALI, without im-
portant adverse effects [20].
5. Other drugs may potentially limit endothelial
dysfunction and thromboinflammation during
SARS-CoV-2 infection. Dipyridamole (DIP) has
been recently shown to exert a protective effect in
experimental studies, as it was clinically associated
with increased platelet counts and decreased D-
dimer levels. Furthermore, in both in vitro and ani-
mal studies, it suppressed SARS-CoV-2 replication
and promoted a type I interferon (IFN) response
[21]. Recent studies suggested that the preservation
of endothelial Tie2 expression protects the vascula-
ture against thrombus formation in systemic inflam-
mation by limiting endothelial TF expression and
fibrin accumulation. In quiescent endothelial cells,
angiopoietin-1 stimulates Tie2, but during inflam-
mation, angiopoietin-2 competitively inhibits Tie2,
favoring endothelial dysfunction that could be tar-
geted using adenoviral constructs expressing the
protective angiopoietin-1.
6. Another crucial mechanism in SARS-CoV-2-associ-
ated inflammatory response is the triggering of
complement cascade with deposition of the final
component C5b-9 and endothelial cell lysis. Thera-
peutically, drugs developed to block the comple-
ment system may modulate the deregulated
inflammatory response in COVID-19. C3 inhibitors,
such as AMY-101, already tested in humans, could
have a beneficial role by early complement block-
ade. A specific antibody against C5a receptor
(C5aR) was employed in mice infected with MERS-
CoV and effectively blunted lung injury [22]. Last,
Diurno et al. described a case series of 4 COVID-19
patients with severe pneumonia treated with eculi-
zumab: of note, the authors reported improvement
of clinical signs, CT scan lung lesions, and labora-
tory tests within 48 h of first administration [23].
7. Regenerative medicine with the use of different
types of stem cells has been proposed in recent
years for the cure of acute and chronic diseases.
Mesenchymal stromal cells (MSC) and endothelial
progenitor cells (EPC) have been studied in pre-
clinical models and in clinical trials enrolling ARDS
patients with promising results. EPC are mobilized
from the bone marrow following vascular injury in
order to induce neoangiogenesis and restore endo-
thelial integrity. In ARDS patients, circulating EPC
increase reflects microvascular damage and corre-
lates with survival [24]. Moreover, in experimental
models of acute lung injury, EPC transplantation re-
duced edema and hyaline membrane formation fa-
voring endothelium repair.
On this basis, more than 30 clinical trials using MSC
in COVID-19 are currently ongoing. The therapeutic po-
tential of MSC is based on a dual beneficial effect: in-
duction of a regenerative program in the lung epithelial
and endothelial cells and simultaneous modulation of
the inflammatory response (mainly by increased gener-
ation of T regulatory cells).
Of note, the protective role of stem cells is mainly due
to the release of paracrine molecules including extracel-
lular vesicles (EV). EV are microparticles that have a role
in cell-to-cell communication through the transfer of
proteins, membrane receptors, lipids, and genetic mater-
ial such as mRNA and microRNA. Several experimental
studies demonstrated the protective role of MSC- and
EPC-derived EV in ARDS [25].
Conclusions
In conclusion, we herein describe the relevance of
thromboinflammation and endothelial dysfunction in
COVID-19 patients. Microvascular derangement is a key
mechanism of multiple organ dysfunction and thera-
peutic strategies other than heparin, aimed at preserving
endothelial integrity, should be considered to win this
war to the knife.
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